Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03101358 · ClinicalTrials.gov registry record · Phase 1
Study of Topical SOR007 Ointment for Cutaneous Metastases
A Phase 1 study, sponsored by NanOlogy.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03101358: Completed Phase 1 study, sponsored by NanOlogy.
NCT03101358 is a Phase 1 study that has completed, run by NanOlogy. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03101358, a Phase 1 study, has completed, sponsored by NanOlogy.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum tolerated dose.
Primary Outcome
Treatment emergent adverse events will include all reported adverse events, laboratory assessments, physical examination findings, and vital signs.
Interventions
- DRUG SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2020-04-29 |
| Phase | Phase 1 |
What the finished NCT03101358 record still lists
NCT03101358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment is the first listed.
NCT03101358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03101358 about?
NCT03101358 is a clinical study titled "Study of Topical SOR007 Ointment for Cutaneous Metastases". This study evaluates a topical nanoparticle paclitaxel ointment (SOR007) for the treatment of cutaneous metastases from non-melanoma cancer in adults. Three concentrations of SOR007 will be evaluated in dose-rising cohorts of three. An expanded cohort will treat additional subjects at the maximum to...
What is the current status of trial NCT03101358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-01-31. Estimated completion is 2020-04-29.
What interventions are being tested in trial NCT03101358?
The interventions under investigation include: SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment (DRUG).
Who is sponsoring clinical trial NCT03101358?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03101358's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI